Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. reports developments tied to its computational platform for molecular discovery, which is licensed to biotechnology, pharmaceutical, industrial and academic customers for drug development and materials design. Company updates commonly cover Software segment performance, hosted and license-server delivery, annual contract value, and the role of software revenue in the business.
News also addresses Schrödinger's Drug Discovery segment, including collaborative and internal programs, together with clinical or regulatory disclosures when applicable. Recurring corporate items include quarterly and annual financial results, investor conference participation, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), shareholder voting matters, governance changes and capital-structure disclosures.
Schrödinger (NASDAQ: SDGR) reported Q1 2026 results: ACV $28.4M (+12%), trailing four-quarter ACV $201M, total revenue $58.6M (down 2%), and net loss $60.0M. Software revenue declined as the company accelerates transition to hosted licensing; drug discovery revenue rose to $22.9M. Cash and equivalents totaled $406M. Guidance for 2026 was maintained: ACV $218–228M and drug discovery revenue $55–65M. The company announced an early-access release of Bunsen, an agentic AI co-scientist, this summer.
Schrödinger (Nasdaq: SDGR) announced management will participate in two investor conferences in May 2026: a BofA Securities healthcare fireside chat on May 13, 2026 at 5:20 p.m. ET and an RBC healthcare fireside chat on May 19, 2026 at 2:05 p.m. ET.
Live discussions are available in the Investors section of the company website and will be archived for approximately 90 days after each event.
Schrödinger (Nasdaq: SDGR) will report first quarter 2026 financial results on May 5, 2026 after the financial markets close. The company will host a conference call and live webcast at 4:30 p.m. ET.
The live webcast will be accessible in the Investors section of Schrödinger’s website and will be archived for approximately 90 days following the event.
Schrödinger (Nasdaq: SDGR) reported inducement restricted stock unit (RSU) grants on April 16, 2026, covering 4,253 shares awarded to four newly hired employees under its 2021 Inducement Equity Incentive Plan.
According to the company, the RSUs vest over four years: 25% after 12 months, then three equal annual installments thereafter, and are subject to award agreements and plan terms.
Schrödinger (Nasdaq: SDGR) disclosed inducement equity awards granted March 14, 2026 to newly hired employees under its 2021 Inducement Equity Incentive Plan.
The company granted a non‑statutory option for 1,950 shares at an exercise price of $12.51 (closing price March 13, 2026) and 4,375 RSUs. Options have a 10‑year term and vest over four years; RSUs vest over four years.
Schrödinger (Nasdaq: SDGR) reported 2025 total revenue of $255.9M (up 23.3%) and software revenue of $199.5M (up 10.6%).
Key metrics: 2025 software ACV $198.5M, hosted revenue 23% of software, software gross margin 74%, cash and marketable securities ~$402.3M, and a 2028 objective to reach positive adjusted EBITDA.
Schrödinger (Nasdaq: SDGR) said management will attend three investor conferences in March 2026 with scheduled fireside chats on March 3, March 10, and March 17.
The live discussions will be available in the company’s Investors section and archived for approximately 90 days after each event.
Schrödinger (Nasdaq: SDGR) reported inducement equity awards granted on February 13, 2026 to newly hired employees under its 2021 Inducement Equity Incentive Plan.
The company granted 9,600 non‑statutory stock options to two hires and 18,250 RSUs to eight hires. Options exercise price: $11.40 (closing price on February 13, 2026). Options have a 10‑year term; both award types vest over four years per stated schedules.
Schrödinger (NASDAQ: SDGR) will report its fourth-quarter and full-year 2025 financial results on Wednesday, February 25, 2026 after market close. The company will host a conference call and live webcast at 4:30 p.m. ET, with the webcast available in Investors and archived for ~90 days.
Schrödinger (Nasdaq: SDGR) summarized 2025 progress and laid out 2026 priorities to scale its physics+AI computational platform and expand drug discovery collaborations. Key 2025 milestones include strategic agreements with Lilly and Manas AI, a beta Predictive Toxicology solution covering ~50 kinases, 20 peer-reviewed publications, and initial Phase 1 clinical data for SGR-1505. Regulatory recognitions include Fast Track and Orphan Drug designations for SGR-1505 in Waldenström macroglobulinemia. 2026 priorities focus on platform scaling, completing Phase 1 data for SGR-1505 and SGR-3515, presenting SGR-3515 data H1 2026, and pursuing partnerships to advance clinical programs.